Clinical Trial Update: High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating high-dose therapy with autologous stem cell transplant followed by infusion of CD19-directed CAR-T cells in patients with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CD19-directed CAR-T cells (CD19-directed chimeric antigen receptor T cells)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Non-Hodgkin's Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING